TG Therapeutics (NASDAQ:TGTX) Share Price Crosses Above 200-Day Moving Average of $6.83

Shares of TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of recent research reports. StockNews.com raised TG Therapeutics to a “sell” rating in a report on Friday, June 17th. B. Riley reduced their price target on TG Therapeutics from $23.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 13th. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $21.25.

TG Therapeutics Stock Down 2.1 %

The company has a fifty day simple moving average of $6.83 and a 200-day simple moving average of $6.83. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.53. The firm has a market cap of $957.36 million, a P/E ratio of -3.05 and a beta of 2.19.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas grew its stake in TG Therapeutics by 22.3% in the fourth quarter. Teacher Retirement System of Texas now owns 23,077 shares of the biopharmaceutical company’s stock worth $438,000 after purchasing an additional 4,203 shares in the last quarter. Bank of Montreal Can raised its stake in shares of TG Therapeutics by 6,513.7% during the 4th quarter. Bank of Montreal Can now owns 77,777 shares of the biopharmaceutical company’s stock valued at $1,530,000 after buying an additional 76,601 shares during the last quarter. Allianz Asset Management GmbH raised its stake in shares of TG Therapeutics by 1.8% during the 4th quarter. Allianz Asset Management GmbH now owns 279,206 shares of the biopharmaceutical company’s stock valued at $5,311,000 after buying an additional 4,837 shares during the last quarter. Ensign Peak Advisors Inc purchased a new position in shares of TG Therapeutics during the 4th quarter valued at about $599,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of TG Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 938,394 shares of the biopharmaceutical company’s stock valued at $17,830,000 after acquiring an additional 23,927 shares during the period. 72.64% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Featured Articles

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.